Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,633,706
  • Shares Outstanding, K 347,597
  • Annual Sales, $ 62,900 K
  • Annual Income, $ -204,630 K
  • EBIT $ -213 M
  • EBITDA $ -211 M
  • 60-Month Beta 1.60
  • Price/Sales 25.42
  • Price/Cash Flow N/A
  • Price/Book 5.21

Options Overview Details

View History
  • Implied Volatility 82.69% (-22.26%)
  • Historical Volatility 97.17%
  • IV Percentile 11%
  • IV Rank 3.62%
  • IV High 479.42% on 04/17/25
  • IV Low 67.79% on 07/22/25
  • Expected Move (DTE 3) 0.26 (5.26%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 347
  • Volume Avg (30-Day) 1,045
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 35,431
  • Open Int (30-Day) 48,175
  • Expected Range 4.60 to 5.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.12
  • Number of Estimates 4
  • High Estimate $0.38
  • Low Estimate $0.01
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +175.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.05 +19.90%
on 03/30/26
4.91 -1.22%
on 04/14/26
+0.41 (+9.23%)
since 03/13/26
3-Month
4.05 +19.90%
on 03/30/26
6.47 -25.04%
on 01/15/26
-1.46 (-23.14%)
since 01/14/26
52-Week
1.57 +208.92%
on 06/16/25
9.75 -50.26%
on 12/22/25
+2.83 (+140.10%)
since 04/14/25

Most Recent Stories

More News
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline

NUVB : 4.85 (+3.19%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised...

NUVB : 4.85 (+3.19%)
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (“NUVB” or “the Company”) (NYSE:...

NUVB : 4.85 (+3.19%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB).  Such investors are advised...

NUVB : 4.85 (+3.19%)
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to...

NUVB : 4.85 (+3.19%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB).  Such investors are advised...

NUVB : 4.85 (+3.19%)
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

NEW YORK , March 6, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) ...

NUVB : 4.85 (+3.19%)
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025

NUVB : 4.85 (+3.19%)
Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK , Feb. 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 4.85 (+3.19%)
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

NEW YORK , Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will...

NUVB : 4.85 (+3.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 5.12
2nd Resistance Point 5.02
1st Resistance Point 4.93
Last Price 4.85
1st Support Level 4.74
2nd Support Level 4.64
3rd Support Level 4.55

See More

52-Week High 9.75
Fibonacci 61.8% 6.63
Fibonacci 50% 5.66
Last Price 4.85
Fibonacci 38.2% 4.69
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.